Results 101 to 110 of about 1,214 (169)

Precision Thyroid Oncology: A Review of Multi-Omics Biomarkers and Spatiotemporal Technologies. [PDF]

Int J Gen Med
Huang L, Deng X, Xi Z, Huan X, Mao J, Li X.   +5 more
europepmc   +1 more source

LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive (RET+) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC. [PDF]

Lung Cancer (Auckl)
Lee ATM, Ou SI.
europepmc   +1 more source

Long-term safety of selpercatinib for Rearranged during transfection (RET)-activated advanced solid tumors in LIBRETTO-001: differing patterns of adverse events over time. [PDF]

Oncologist
Raez LE, Massey AC, Barker SS, Peterson PM, Liming K, Pennell NA.   +5 more
europepmc   +1 more source

Assessing tolerability with the Functional Assessment of Cancer Therapy item GP5: psychometric evidence from LIBRETTO-531, a phase 3 trial of selpercatinib in medullary thyroid cancer. [PDF]

J Patient Rep Outcomes
Regnault A, Bunod L, Loubert A, Brose MS, Hess LM, Maeda P, Lin Y, Speck RM, Gilligan AM, Payakachat N.   +9 more
europepmc   +1 more source

The Utility of Tissue-Agnostic Drugs in Lung Cancer Treatment. [PDF]

Pharmaceut Med
Kong L, Grobman B, Mansur A, Lee A, Bondarchuk C, Erdogan H, Lu CY.   +6 more
europepmc   +1 more source

Case Report: Complete pathologic response to neoadjuvant immunotherapy-chemotherapy in a patient with RET fusion-positive non-small cell lung cancer. [PDF]

Front Oncol
Wang Y, Zhang Y, Cai C, Liu X, Ren S, Zhou S.   +5 more
europepmc   +1 more source

Durability of Response With Selpercatinib in Patients With <i>RET</i>-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. [PDF]

J Clin Oncol
Wirth LJ, Brose MS, Subbiah V, Worden F, Solomon B, Robinson B, Hadoux J, Tomasini P, Weiler D, Deschler-Baier B, Tan DSW, Maeda P, Lin Y, Singh R, Bayt T, Drilon A, Cassier PA.   +16 more
europepmc   +1 more source

Round-Robin Comparison of RET Rearrangement Detection in ctDNA: A Novel Method for Limited Clinical Samples. [PDF]

Clin Cancer Res
Paweletz CP, Urvalek A, Ha M, Garg K, Bence Lin A, Szpurka AM, Sireci A, Oxnard GR, Janne PA.   +8 more
europepmc   +1 more source

Metastatic Medullary Thyroid Carcinoma in Multiple Endocrine Neoplasia Type 2B (MEN 2B) With RET M918T Mutation: Challenges in Long-Term Management and Targeted Therapy. [PDF]

Cureus
Rahman Z, Clark B, Ali K, Choudhry H, Weimer L, Parza K, Bastidas Mora G.   +6 more
europepmc   +1 more source